Till Uhlig

University of Oslo — Norway

Medicine · Health Sciences

60h-index13.4kcitations368works4.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Rheumatoid Arthritis Research and Therapies(221), Systemic Lupus Erythematosus Research(73), Gout, Hyperuricemia, Uric Acid(54), Autoimmune and Inflammatory Disorders Research(54), Spondyloarthritis Studies and Treatments(35)

Publications368 total

Ultrasound-detected crystal depositions and clinical flares dissolve during successful urate-lowering therapy: 5-year follow-up results from the treat-to-target NOR-Gout study
Annals of the Rheumatic Diseases·2025Open Access
Correction: Disease activity and treatment response in early rheumatoid arthritis: an exploratory metabolomic profiling in the NORD-STAR cohort
Arthritis Research & Therapy·2025Open Access
Health-Related Quality of Life in Disease-Modifying Antirheumatic Drug–Treated Adults With Juvenile Idiopathic Arthritis Compared to Rheumatoid Arthritis and the General Population
The Journal of Rheumatology·2025
Perceptions About Asymptomatic Hyperuricemia and Views About Urate‐Lowering Therapy in People With Asymptomatic Hyperuricemia
Arthritis Care & Research·2025· 1 citedOpen Access
Low Th2 and high PD1+ TFh cells in blood predict remission after CTLA-4Ig treatment for 48 weeks in early rheumatoid arthritis
PLoS ONE·2025· 1 citedOpen Access
Acylcarnitine enrichment as a characteristic of rheumatoid arthritis fibroblast-like synoviocyte metabolic fingerprint
Journal of Translational Autoimmunity·2025Open Access
Let us avoid fluctuations in serum urate in gout
Clinical Rheumatology·2025Open Access
Disease activity and treatment response in early rheumatoid arthritis: an exploratory metabolomic profiling in the NORD-STAR cohort
Arthritis Research & Therapy·2025· 4 citedOpen Access
Association of Soluble Immune Checkpoint Molecules <scp>PD1</scp> and 4‐<scp>1BB</scp> With <scp>CTLA</scp>‐<scp>4Ig</scp> Treatment Response in Early Rheumatoid Arthritis
ACR Open Rheumatology·2025Open Access
Glucocorticoid treatment in early rheumatoid arthritis is independently associated with increased PCSK9 levels: data from a randomised controlled trial
RMD Open·2025· 1 citedOpen Access
POS1198 REMONIT GOUT FEASIBILITY STUDY: A SELF-MANAGEMENT APP IN A TREAT-TO-TARGET GOUT CARE APPROACH
Annals of the Rheumatic Diseases·2025Open Access
POS1475-HPR EXPLORING CHANGES IN BENEFIT STATUS IN THE YEAR BEFORE AND AFTER REHABILITATION: A CASE-CONTROL STUDY.
Annals of the Rheumatic Diseases·2025Open Access
POS0294 HEALTH-RELATED QUALITY OF LIFE IN ADULTS WITH JUVENILE IDIOPATHIC ARTHRITIS COMPARED TO PATIENTS WITH RHEUMATOID ARTHRITIS AND THE GENERAL POPULATION: DATA ON DMARD-TREATED PATIENTS FROM NOR-DMARD
Annals of the Rheumatic Diseases·2025Open Access
Epitopes targeted by autoantibodies in presymptomatic individuals predict early rheumatoid arthritis
Annals of the Rheumatic Diseases·2025· 1 citedOpen Access
Three‐Year Results of Tapering Tumor Necrosis Factor Inhibitor to Withdrawal Compared to Stable Tumor Necrosis Factor Inhibitor Among Patients With Rheumatoid Arthritis in Sustained Remission: A Multicenter Randomized Trial
Arthritis & Rheumatology·2025· 1 citedOpen Access
Transitional and CD21− PD-1+ B cells are associated with remission in early rheumatoid arthritis
BMC Rheumatology·2025· 1 citedOpen Access
Treatment with methotrexate plus oral prednisolone versus triple therapy (methotrexate/sulfasalazine/hydroxychloroquine) plus intra-articular glucocorticoids in early rheumatoid arthritis: a prespecified nonrandomised subgroup analysis of clinical and radiographic data at 48 weeks from the NORD-STAR trial's conventional treatment arm
Annals of the Rheumatic Diseases·2025· 5 citedOpen Access
Remission in gout is possible: 5-year follow-up in the NOR-Gout study
Seminars in Arthritis and Rheumatism·2025· 4 citedOpen Access
Certolizumab pegol, Abatacept, Tocilizumab or Active Conventional Therapy in Early Rheumatoid Arthritis: 48 Week Patient-Reported Outcomes of the NORD-STAR Trial
SSRN Electronic Journal·2025Open Access
Comment on: Longitudinal risk of serious infections in patients with inflammatory arthritis on immunomodulating therapy compared to controls: Reply
Rheumatology Advances in Practice·2025Open Access
page 1 of 19Next →

Frequent Co-authors

Tore K Kvien(27), Fernando Pérez-Ruiz(9), Espen A. Haavardsholm(8), Tim Jansen(7), Glenn Haugeberg(7), Francisca Sivera(7), Désirée van der Heijde(7), Petter Mowinckel(7), Sigrid Ødegård(6), Annelies Boonen(6), Pascal Richette(5), Michael Doherty(5), Eliseo Pascual(5), M. Janssen(5), Thomas Bardin(5), Hilde Berner Hammer(5), Anthony D. Woolf(5), William J. Taylor(5), Nicola Dalbeth(5), Worawit Louthrenoo(5)